Urogen Pharma Ltd. (UR8)
XDUS 
Summary
UR8 Chart
UroGen Pharma: An Emerging GARP Stock
UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri's strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri's rapid uptake, favorable patient preference, and robust clinical data support continued growth, with patent protection until 2044 and 95% reimbursement coverage. URGN faces looming clinical competition but currently only contends with TURBT, positioning it for robust growth through at least 2027.
Urogen Pharma: Upside After Bladder Cancer Launch
UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely.
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Urogen Pharma Ltd. (UR8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Urogen Pharma Ltd. ever had a stock split?
Urogen Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Elizabeth Barrett CEO | XDUS Exchange | IL0011407140 ISIN |
| US Country | 300 Employees | - Last Dividend | - Last Split | 4 May 2017 IPO Date |
Overview
UroGen Pharma Ltd. is a pioneering biotechnology company dedicated to developing innovative solutions for specialty cancers and urothelial diseases. Founded in 2004 and headquartered in Princeton, New Jersey, the company specializes in creating advanced treatments that aim to significantly improve the lives of patients suffering from these conditions. UroGen Pharma's approach combines the use of its proprietary RTGel technology with strategic partnerships and collaborations, such as those with Agenus Inc. and MD Anderson, to develop and commercialize effective therapies for the treatment of cancers of the urinary tract.
Products and Services
- RTGel
- Jelmyto
- UGN-102
- UGN-301
A novel polymeric biocompatible and reverse thermal gelation hydrogel designed to enhance the therapeutic profiles of existing drugs. RTGel's unique properties allow it to transform from a liquid to a gel at body temperature, enabling sustained release and targeted delivery of therapeutics directly to the site of the disease.
An innovative treatment option for pyelocalyceal solution, Jelmyto leverages UroGen Pharma's RTGel technology to treat urothelial carcinoma. This therapy represents a significant advancement in the management of this form of cancer, offering patients a minimally invasive treatment option.
UroGen Pharma's lead product candidate, UGN-102, is under development for the treatment of low-grade non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. By targeting these conditions, UGN-102 aims to provide a new therapeutic approach for patients with these types of cancer.
Another exciting development from UroGen Pharma is UGN-301, currently being developed for the treatment of high-grade non-muscle invasive bladder cancer. This candidate underscores the company's commitment to expanding its portfolio of treatments for various stages and grades of bladder cancer, aiming to address the unmet needs in this therapeutic area.
Contact Information
